| oxaliplatin / Generic mfg. |
| Terminated | 2 | 9 | US | Capecitabine, Xeloda, Oxaliplatin, Eloxatin | Dana-Farber Cancer Institute, National Cancer Institute (NCI), Sanofi-Synthelabo | Head and Neck Cancer | 03/07 | 03/08 | | |
NCT00184028: Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck |
|
|
| Terminated | 2 | 12 | US | Taxotere, Oxaliplatin | University of Southern California, Sanofi | Carcinoma of the Head and Neck | 07/09 | 07/10 | | |
NCT00557206: Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer |
|
|
| Terminated | 2 | 35 | US | Oxaliplatin and Docetaxel | Minneapolis Veterans Affairs Medical Center, Sanofi | Neoplasms, Head and Neck Neoplasms | 11/09 | 11/09 | | |
NCT00256308: Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer |
|
|
| Terminated | 2 | 6 | US | Oxaliplatin, Eloxatin, Radiation | University of California, Irvine, Sanofi | Head and Neck Cancer | 05/10 | 10/11 | | |
NCT00591149: Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer |
|
|
| Terminated | 2 | 16 | US | Oxaliplatin, Eloxatin, Docetaxel, Taxotere, Cetuximab, Erbitux | University of Kansas Medical Center, Sanofi | Head and Neck Cancer, Carcinoma, Squamous | 04/12 | 04/12 | | |
